U.S. Induced Pluripotent Stem Cells (iPSCs) Market - Industry Trends and Forecast to 2031

Description

List of Tables

The U.S. induced pluripotent stem cells (iPSCs) market is expected to reach USD 488.42 million by 2031 from USD 218.87 million in 2023, growing at a CAGR of 10.7% in the forecast period of 2024 to 2031.

Market Segmentation

U.S. Induced Pluripotent Stem Cells (iPSCs) Market, By Model Type (ECM-Patterned PAA/ PDMS Substrates, Microgroove PDMS Substrates, Strained Membranes, 3D Sacffolds, Free-Floating Hydrogel Contructs, and EHTS), Material (Natural Hydrogel Based Cardiac Models and Synthetic Fibrous Cardiac Models), Cell Source (Skin Cells and Blood Cells), Dimensional Type (2D and 3D), Application (Production of New Cardiac Tissue To Replace Tissue Destroyed By Infraction Or Other Diseases, Heart Failure, Ischemic Heart Disease, Arrhythmia, Cardiomyopathies, Valvular Heart Disease, Heart Disease Screening, and Others), End Use (Pharmaceutical & Biotechnology Companies, Academic and Government Research Institutes, Contract Development & Manufacturing Organizations, and Others ), Distribution Channel (Direct Tender and Retail Sales) Country (U.S.) - Industry Trends and Forecast to 2031.

Overview of U.S. Induced Pluripotent Stem Cells (iPSCs) Market Dynamics

Driver
Technological advancement in regenerative medicine
Restraint
Safety concerns and technical difficulties
Opportunity
Increasing interest in personalized medicine

Market Players

Some of the major market players operating in the U.S. induced pluripotent stem cells (iPSCs) market are:

Corning Incorporated
Lonza
MIMETAS
CN Bio Innovations Ltd
3D BIOTEK LLC
AXOL
REPROCELL Inc.

1 INTRODUCTION 11

1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 11
1.3 OVERVIEW OF U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 11
1.4 CURRENCY AND PRICING 12
1.5 LIMITATIONS 12
1.6 MARKETS COVERED 13

2 MARKET SEGMENTATION 15

2.1 MARKETS COVERED 15
2.2 YEARS CONSIDERED FOR THE STUDY 16
2.3 DBMR TRIPOD DATA VALIDATION MODEL 17
2.4 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20
2.5 DBMR MARKET POSITION GRID 21
2.6 MULTIVARIATE MODELLING 22
2.7 TYPE LIFELINE CURVE 23
2.8 MARKET END USER COVERAGE GRID 24
2.9 SECONDARY SOURCES 25
2.10 ASSUMPTIONS 25

3 EXECUTIVE SUMMARY 26

4 PREMIUM INSIGHTS 29

4.1 PESTEL ANALYSIS 30
4.2 PORTER'S FIVE FORCES 31

5 MARKET OVERVIEW 32

5.1 DRIVERS 34
- 5.1.1 TECHNOLOGICAL ADVANCEMENT IN REGENERATIVE MEDICINE 34
- 5.1.2 EXPANDING APPLICATIONS IN DRUGS DISCOVERY 34
5.2 RESTRAINTS 35
- 5.2.1 SAFETY CONCERNS AND TECHNICAL DIFFICULTIES 35
- 5.2.2 COMPETITION AND INTELLECTUAL PROPERTY ISSUES 36
5.3 OPPORTUNITIES 36
- 5.3.1 INCREASING INTEREST OF PERSONALIZED MEDICINE 36
- 5.3.2 INCREASING ADOPTION OF STEM CELL THERAPY 37
5.4 CHALLENGE 38
- 5.4.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES 38

6 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY MODEL TYPE 39

6.1 OVERVIEW 40
6.2 ECM PATTERNED PAA/PDMS SUBSTRATES 43
6.3 MICROGROOVE PDMS SUBSTRATES 43
6.4 STRAINED MEMBRANES 43
6.5 3D SACFFOLDS 43
6.6 FREE-FLOATING HYDROGEL CONTRUCTS 43
6.7 EHTS 43

7 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY MATERIAL 44

7.1 OVERVIEW 45
7.2 NATURAL HYDROGEL- BASED CARDIAC MODELS 48
7.3 SYNTHETICS FIBROUS CARDIAC MODELS 48
- 7.3.1 POLYGLYCOLIC ACID (PGA) 48
- 7.3.2 POLY E-CAPROLACTONE (PCL) 48
- 7.3.3 POLYURETHANE 48
- 7.3.4 POLYLACTIC ACID (PLA) 49
- 7.3.5 OTHERS 49

8 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE 50

8.1 OVERVIEW 51
8.2 SKIN CELLS 54
- 8.2.1 FIBROBLAST 54
- 8.2.2 KERATINOCYTES 54
- 8.2.3 MELANOCYTES 54
- 8.2.4 NEURAL STEM CELLS 54
- 8.2.5 ADIPOSE DERIVE STEM CELLS 54
- 8.2.6 OTHERS 55
8.3 BLOOD CELLS 55
- 8.3.1 PERIPHERAL BLOOD MONOCLEAR CELLS 55
- 8.3.2 CORD BLOOD ENDOTHELIAL CELLS 55
- 8.3.3 CORD BLOOD STEM CELLS 55
- 8.3.4 OTHERS 55

9 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DIMENSIONAL TYPE 56

9.1 OVERVIEW 57
9.2 3D 60
9.3 SKIN CELLS 60
- 9.3.1 FIBROBLAST 60
- 9.3.2 KERATINOCYTES 61
- 9.3.3 MELANOCYTES 61
- 9.3.4 NEURAL STEM CELLS 61
- 9.3.5 ADIPOSE DERIVE STEM CELLS 61
- 9.3.6 OTHERS 61
9.4 BLOOD CELLS 61
- 9.4.1 PERIPHERAL BLOOD MONOCLEAR CELLS 62
- 9.4.2 CORD BLOOD ENDOTHELIAL CELLS 62
- 9.4.3 CORD BLOOD STEM CELLS 62
- 9.4.4 OTHERS 62
9.5 2D 62
- 9.5.1 SKIN CELLS 62
  - 9.5.1.1 FIBROBLAST 63
  - 9.5.1.2 KERATINOCYTES 63
  - 9.5.1.3 MELANOCYTES 63
  - 9.5.1.4 NEURAL STEM CELLS 63
  - 9.5.1.5 ADIPOSE DERIVE STEM CELLS 63
  - 9.5.1.6 OTHERS 63
- 9.5.2 BLOOD CELLS 64
  - 9.5.2.1 PERIPHERAL BLOOD MONOCLEAR CELLS 64
  - 9.5.2.2 CORD BLOOD ENDOTHELIAL CELLS 64
  - 9.5.2.3 CORD BLOOD STEM CELLS 64
  - 9.5.2.4 OTHERS 64

10 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION 65

10.1 OVERVIEW 66
10.2 PRODUCTION OF NEW CARDIAC TISSUE TO REPLACE TISSUES DESTROYED BY INFRACTION OR OTHER DISEASES 70
10.3 HEART FAILURE 70
10.4 ISCHEMIC HEART DISEASE 70
10.5 ARRYTHMIA 70
10.6 CARDIOMYOPATHIES 70
10.7 VALVULAR HEART DISEASE 70
10.8 HEART DISEASE SCREENING 70
10.9 OTHERS 70

11 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USE 71

11.1 OVERVIEW 72
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 75
11.3 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 75
11.4 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS 75
11.5 OTHERS 75

12 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL 76

12.1 OVERVIEW 77
12.2 DIRECT TENDER 80
12.3 RETAIL SALES 80

13 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE 81

13.1 COMPANY SHARE ANALYSIS: U.S. 81

14 SWOT ANALYSIS 82

15 COMPANY PROFILE 83

15.1 CORNING INCRPORATED 83
- 15.1.1 COMPANY SNAPSHOT 83
- 15.1.2 REVENUE ANALYSIS 83
- 15.1.3 PRODUCT PORTFOLIO 84
- 15.1.4 RECENT DEVELOPMENT 85
15.2 LONZA 86
- 15.2.1 COMPANY SNAPSHOT 86
- 15.2.2 REVENUE ANALYSIS 86
- 15.2.3 PRODUCT PORTFOLIO 87
- 15.2.4 RECENT DEVELOPMENT 88
15.3 MIMETAS 89
- 15.3.1 COMPANY SNAPSHOT 89
- 15.3.2 PRODUCT PORTFOLIO 89
- 15.3.3 RECENT DEVELOPMENT 89
15.4 REPROCELL INC. 90
- 15.4.1 COMPANY SNAPSHOT 90
- 15.4.2 PRODUCT PORTFOLIO 90
- 15.4.3 RECENT DEVELOPMENT 91
15.5 CN BIO INNOVATIONS 92
- 15.5.1 COMPANY SNAPSHOT 92
- 15.5.2 PRODUCT PORTFOLIO 92
- 15.5.3 RECENT DEVELOPMENT 93
15.6 AXOL BIOSCIENCE LTD. 94
- 15.6.1 COMPANY SNAPSHOT 94
- 15.6.2 PRODUCT PORTFOLIO 94
- 15.6.3 RECENT DEVELOPMENT 94
15.7 3D BIOTEK LLC. 95
- 15.7.1 COMPANY SNAPSHOT 95
- 15.7.2 PRODUCT PORTFOLIO 95
- 15.7.3 RECENT DEVELOPMENT 96

16 QUESTIONNAIRE 97

17 RELATED REPORTS 100

LIST OF TABLES

TABLE 1 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY MODEL TYPE, 2022- 2031 (USD MILLION) 42
TABLE 2 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY MATERIAL, 2022- 2031 (USD MILLION) 47
TABLE 3 U.S. SYNTHETIC FIBROUS CARDIAC MODELS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY MATERIAL, 2022-2031 (USD MILLION) 48
TABLE 4 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2022- 2031 (USD MILLION) 53
TABLE 5 U.S. SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2022- 2031 (USD MILLION) 54
TABLE 6 U.S. BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2022- 2031 (USD MILLION) 55
TABLE 7 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DIMENSIONAL TYPE, 2022- 2031 (USD MILLION) 59
TABLE 8 U.S. 3D IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2022-2031 (USD MILLION) 60
TABLE 9 U.S. SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2022- 2031 (USD MILLION) 60
TABLE 10 U.S. BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2022- 2031 (USD MILLION) 61
TABLE 11 U.S. 2D IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2022- 2031 (USD MILLION) 62
TABLE 12 U.S. SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2022- 2031 (USD MILLION) 63
TABLE 13 U.S. BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2022- 2031 (USD MILLION) 64
TABLE 14 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2022- 2031 (USD MILLION) 69
TABLE 15 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USE, 2022- 2031 (USD MILLION) 74
TABLE 16 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2022- 2031 (USD MILLION) 79

LIST OF FIGURES

FIGURE 1 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SEGMENTATION 15
FIGURE 2 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DATA TRIANGULATION 17
FIGURE 3 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DROC ANALYSIS 18
FIGURE 4 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COUNTRY VS REGIONALMARKET ANALYSIS 19
FIGURE 5 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS)MARKET: COMPANY RESEARCH ANALYSIS 19
FIGURE 6 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: INTERVIEW DEMOGRAPHICS 20
FIGURE 7 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DBMR MARKET POSITION GRID 21
FIGURE 8 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: MARKET END USER COVERAGE GRID 24
FIGURE 9 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SEGMENTATION 28
FIGURE 10 INCREASING TECHNOLOGICAL ADVANCEMENT IN REGENRATIVE MEDICINE IS DRIVING THE GROWTH OF U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 29
FIGURE 11 MODEL TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKETIN 2024 & 2031 29
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 33
FIGURE 13 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY MODEL TYPE, 2023 40
FIGURE 14 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY MODEL TYPE, 2024-2031 (USD MILLION) 41
FIGURE 15 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY MODEL TYPE, CAGR (2024-2031) 41
FIGURE 16 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY MODEL TYPE, LIFELINE CURVE 42
FIGURE 17 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY MATERIAL, 2023 45
FIGURE 18 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY MATERIAL, 2024-2031 (USD MILLION) 46
FIGURE 19 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY MATERIAL, CAGR (2024-2031) 46
FIGURE 20 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY MATERIAL, LIFELINE CURVE 47
FIGURE 21 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, 2023 51
FIGURE 22 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, 2024-2031 (USD MILLION) 52
FIGURE 23 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, CAGR (2024-2031) 52
FIGURE 24 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, LIFELINE CURVE 53
FIGURE 25 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DIMENSIONAL TYPE, 2023 57
FIGURE 26 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DIMENSIONAL TYPE, 2024-2031 (USD MILLION) 58
FIGURE 27 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DIMENSIONAL TYPE, CAGR (2024-2031) 58
FIGURE 28 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DIMENSIONAL TYPE, LIFELINE CURVE 59
FIGURE 29 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, 2023 66
FIGURE 30 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, 2024-2031 (USD MILLION) 67
FIGURE 31 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, CAGR (2024-2031) 68
FIGURE 32 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, LIFELINE CURVE 69
FIGURE 33 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USE, 2023 72
FIGURE 34 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USE, 2024-2031 (USD MILLION) 73
FIGURE 35 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USE, CAGR (2024-2031) 73
FIGURE 36 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USE, LIFELINE CURVE 74
FIGURE 37 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, 2023 77
FIGURE 38 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 78
FIGURE 39 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 78
FIGURE 40 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 79
FIGURE 41 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY SHARE 2023 (%) 81